ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the more interesting ones. Many of the results had a 2014 cutoff date ( 1 as early as June 2014) so several of these will probably be updated at ASCO at the start of June. In some cases these or very similar results have previously been summarized on this site.

Crizotinib

http://abstracts.asco.org/156/AbstView_156_150033.html  Comparison of ALK detection methods, 98 patients, Nov. 2014 data cutoff

http://abstracts.asco.org/156/AbstView_156_148213.html   Criz & STA 9090, 12 patients

http://abstracts.asco.org/156/AbstView_156_143947.html   Comparison with Ceritinib, 746 patients

http://abstracts.asco.org/156/AbstView_156_152068.html  First line vs second line, 68 patients, 1-29-2015 data cutoff

http://abstracts.asco.org/156/AbstView_156_147967.html   Treatment choices after Criz resistance

Ceritinib

http://abstracts.asco.org/156/AbstView_156_146923.html   Phase 1, 22 Pediatric patients

http://abstracts.asco.org/156/AbstView_156_144861.html   Phase 2, ASCEND 2, 140 patients, prior Criz, Aug. 2014 data cutoff

http://abstracts.asco.org/156/AbstView_156_145907.html   Phase 2, ASCEND 3, 124 patients, Criz naive, 6-27-2014 data cutoff

http://abstracts.asco.org/156/AbstView_156_143947.html   Comparison with Crizotinib, 746 patients

Alectinib

http://abstracts.asco.org/156/AbstView_156_149587.html   46 ALK naive patients in Japan, 10-31-2014 data cutoff

http://abstracts.asco.org/156/AbstView_156_149578.html   Global Phase 2, prior Criz, 138 patients, 8-18-2014 data cutoff

http://abstracts.asco.org/156/AbstView_156_151415.html  U.S. & Canada Phase 2, prior Criz, 87 patients, 10-24-2014 data cutoff

http://abstracts.asco.org/156/AbstView_156_149532.html   Alectinib after Criz, 11 patients

Brigatinib

http://abstracts.asco.org/156/AbstView_156_148225.html   Phase 1/2, 79 ALK+ patients, 8-4-2014 data cutoff

Entrectinib

http://abstracts.asco.org/156/AbstView_156_150911.html   Phase 1/2, 15 patients

http://abstracts.asco.org/156/AbstView_156_149995.html   Phase 1, 31 patients, only a few ALK+

TSR 011

http://abstracts.asco.org/156/AbstView_156_148387.html   Phase 1/2, 46 patients, 19 ALK+

PF 3922

http://abstracts.asco.org/156/AbstView_156_144494.html   Phase 1/2, 22 patients

http://abstracts.asco.org/156/AbstView_156_143329.html   Phase 1/2, 22 patients, efficacy

This entry was posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro. Bookmark the permalink.

Leave a Reply